Immunic, Inc. Aktie News

NEW YORK , Oct. 29, 2025 /PRNewswire/ --  Immunic, Inc.  (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following industry and investor conferences in November: November 3-5: BIO-Europe. Daniel Vitt, Ph.D.

Immunic AG / US4525EP1011

Immunic Inc (NASDAQ:IMUX) Chief Scientific Officer Dr Hella Kohlhof talked with Proactive about the company's research focus on multiple sclerosis (MS), highlighting how Immunic is aiming to address both the physical and mental health challenges faced by patients. Kohlhof explained the strong link between MS and mental health conditions such as depression and anxiety, noting that studies show a...

NEW YORK , Oct. 1, 2025 /PRNewswire/ --  Immunic, Inc.  (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in October: October 4-7: UEGW 2025 – United European Gastroenterology Week. Immunic's R&...

An unheralded New York–listed biotech is chasing one of neurology's biggest goals: a pill that not only tamps down the inflammatory flares of multiple sclerosis but also directly protects the brain from the slow, steady damage that leaves many patients disabled. Immunic Inc (NASDAQ:IMUX) is developing vidofludimus calcium, an oral medicine it says is “first-in-class” because it combines two mec...

Immunic Inc (NASDAQ:IMUX) has presented clinical trial data suggesting its oral therapy, vidofludimus calcium, could help slow disability in patients with progressive multiple sclerosis, a form of the disease that remains difficult to treat. The results were shared at the annual congress of the European Committee for Treatment and Research in Multiple Sclerosis in Barcelona, one of the largest ...

– Vidofludimus Calcium Demonstrated Statistically Significant 24-Week Confirmed Disability Improvement in Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis, With Over Two-Fold Probability Over Placebo in the Overall Study Population and Consistent Effects Across Subtypes – – CALLIPER Data Showed Positive and Consistent Signals for Slowing Disability Progression Across Disability Endpoint...

Immunic AG / US4525EP1011